COST-EFFECTIVENESS ANALYSIS OF INCREASED ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: ECONOMIC EVALUATION OF THE RANDOMISED CONTROLLED LADI TRIAL

Fenna Minke Jansen  ¹     Reinier van Linschoten  ²     Renske Wilhelmina Maria Pauwels     Lisa S. Smits     Wietske Kievit     Paul Boekema  ³     Rachel West  ⁴     Alexander G. L. Bodelier  ⁵     Ingrid A. M. Gisbertz  ⁶     Frank H. J. Wolfhagen  ⁷     Tessa E.H. Römkens  ⁸     Maurice W. M. D. Lutgens  ⁹     Adriaan A. Van Bodegraven  ¹⁰     Bas Oldenburg  ¹¹     Marieke Pierik  ¹²     Maurice G. V. M. Russel  ¹³     Rosalie C. Mallant-Hent  ¹⁴     Pieter C. J. ter Borg  ¹⁵     Jeroen Michiel Jansen  ¹⁶     Sita Jansen  ¹⁷     Adriaan C. I. T. L. Tan  ¹⁸     Frank Hoentjen  ¹⁹     C. Janneke van der Woude    
¹ Radboudumc University Nijmegen Medical Centre, Nijmegen, Netherlands
² Erasmus Medical Centre, Rotterdam, Netherlands
³ Maxima Medical Centre, Eindhoven, Netherlands
⁴ Franciscus Gasthuis & Vlietland, Rotterdam
⁵ Amphia Hospital, Breda, Netherlands
⁶ Bernhoven Hospital, Uden, Netherlands
⁷ Albert Schweitzer Hospital, Dordrecht, Netherlands
⁸ Jeroen Bosch Hospital, 's-Hertogenbosch, Netherlands
⁹ Elisabeth Tweesteden Hospital, Tilburg, Netherlands
¹⁰ Zuyderland Medical Centre, Sittard-Geleen, Netherlands
¹¹ Utrecht Medical Centre, Utrecht, Netherlands
¹² Maastricht University Medical Centre, Maastricht, Netherlands
¹³ Medisch Spectrum Twente Hospital, Enschede, Netherlands
¹⁴ Flevohospital, Almere, Netherlands
¹⁵ Ikazia Hospital, Rotterdam, Netherlands
¹⁶ Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands
¹⁷ Reinier de Graaf Gasthuis, Delft, Netherlands
¹⁸ Canisius Wilhelmina Hospital, Nijmegen, Netherlands
¹⁹ University of Alberta, Edmonton, Canada

Session
Investigator studies in IBD I (Posters)

Conference
UEG Week 2022

Citation
United European Gastroenterology Journal 2022; 10 (Supplement 8)